Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
Phase 3
Completed
- Conditions
- HypercholesterolemiaHypertriglyceridemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 587
- Registration Number
- NCT00092560
Sitosterolemia Extension Study (0653-003)(COMPLETED)
Phase 3
Completed
- Conditions
- Lipid Metabolism, Inborn ErrorsHeart Disease
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 37
- Registration Number
- NCT00092807
An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 129
- Registration Number
- NCT00092729
An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)
Phase 3
Completed
- Conditions
- Lipid Metabolism, Inborn ErrorsHeart Disease
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 30
- Registration Number
- NCT00092898
An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1873
- Registration Number
- NCT00092677
Sitosterolemia Extension Study (0653-004)(COMPLETED)
Phase 3
Completed
- Conditions
- Heart DiseaseLipid Metabolism, Inborn Errors
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 58
- Registration Number
- NCT00092820
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092781
Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesterolemiaHypertriglyceridemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 576
- Registration Number
- NCT00092573
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, SeasonalAsthma, Bronchial
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 831
- Registration Number
- NCT00092885
Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4086
- Registration Number
- NCT00092742